hit counter
Aptinyx Inc. (APTX) Stock News Sentiment & Price - Sentifly
APTX - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Aptinyx Inc. (APTX)

USA
Biotechnology
NASDAQ
APTX Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
APTX Latest news
Seeking Alpha
Neutral
Aptinyx, Inc. (APTX) CEO Norbert Riedel on Q3 2021 Results - Earnings Call Transcript
2021-11-10 01:43

Aptinyx, Inc. (APTX) CEO Norbert Riedel on Q3 2021 Results - Earnings Call Transcript

Business Wire
Neutral
Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights
2021-11-09 16:05

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2021 and provided key business updates across the company's clinical-stage pipeline of novel NMDA receptor modulators. “The coming year promises to be an exciting time for Aptinyx as we approach several major development milestones across each

Business Wire
Neutral
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
2021-10-27 06:47

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment in the company's ongoing Phase 2b study of NYX-2925 for the treatment of painful diabetic peripheral neuropathy (DPN). Patients recently enrolled in the study are completing the 12-week treatment period and 30-day safety follow-up period. The company expec

Business Wire
Neutral
Aptinyx to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
2021-10-25 07:32

EVANSTON, Ill--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 9, 2021 at 5:00 p.m. ET to report third quarter 2021 financial results and discuss recent business highlights. To access the live conference call, please dial (844) 200 6205 (domestic) or (929) 526 1599

Business Wire
Neutral
Aptinyx Appoints Gilmore O'Neill, M.B., M.M.Sc., to Board of Directors
2021-10-20 07:57

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore O'Neill, M.B., M.M.Sc., to the company's board of directors. Dr. O'Neill currently serves as chief medical officer and executive vice president of research and development at Sarepta Therapeutics. “Gilmore brings an exceptional background of experience and leadership

Business Wire
Neutral
Aptinyx to Participate in 2021 Cantor Virtual Global Healthcare Conference
2021-09-20 07:57

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021 at 10:00 a.m. ET. A live webcast of the presentation will be available to view on the “Events and Presentations” page

Business Wire
Neutral
Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures
2021-09-16 06:37

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has entered into a $50 million loan facility and security agreement with K2 HealthVentures (K2HV). The funds will provide general growth capital as Aptinyx advances its late-stage clinical pipeline of novel NMDA modulators. “Access to this capital provides us with additional f

Business Wire
Neutral
Aptinyx to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
2021-08-31 07:57

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually September 13-15, 2021. The presentation will be available on-demand through the H.C. Wainwright conference portal, beginning at 7:00 AM ET on Monday, September 13, 2021. A l

Seeking Alpha
Neutral
Aptinyx Inc. (APTX) CEO Norbert Riedel on Q2 2021 Results - Earnings Call Transcript
2021-08-10 22:49

Aptinyx Inc. (APTX) CEO Norbert Riedel on Q2 2021 Results - Earnings Call Transcript

Business Wire
Neutral
CORRECTING and REPLACING Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights
2021-08-10 17:49

EVANSTON, Ill.--(BUSINESS WIRE)--In the Condensed Balance Sheet, last line should read: Total liabilities and stockholders' equity   $ 134,168   $ 150,606 instead of: Total liabilities and stockholders' equity   $ 134,169   $ 150,606 The updated release reads: APTINYX REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS Enrollment on track in both Phase 2b chronic pain studies with NYX-2925—data readouts expected 1H 2022 Enrollment on track in Phase 2 cognitive impairment study

Loading more news...